209 related articles for article (PubMed ID: 32228243)
1. MDMA interactions with pharmaceuticals and drugs of abuse.
Papaseit E; Pérez-Mañá C; Torrens M; Farré A; Poyatos L; Hladun O; Sanvisens A; Muga R; Farré M
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):357-369. PubMed ID: 32228243
[No Abstract] [Full Text] [Related]
2. Depression, impulsiveness, sleep, and memory in past and present polydrug users of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Taurah L; Chandler C; Sanders G
Psychopharmacology (Berl); 2014 Feb; 231(4):737-51. PubMed ID: 24114426
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Ecstasy influence on tramadol and its main metabolite plasma concentration in rats.
Jamali B; Sheikholeslami B; Hosseinzadeh Ardakani Y; Lavasani H; Rouini MR
Drug Metab Pers Ther; 2017 Sep; 32(3):137-145. PubMed ID: 28917081
[TBL] [Abstract][Full Text] [Related]
4. A Case of 3,4-Dimethoxyamphetamine (3,4-DMA) and 3,4-Methylenedioxymethamphetamine (MDMA) Toxicity with Possible Metabolic Interaction.
Darracq MA; Thornton SL; Minns AB; Gerona RR
J Psychoactive Drugs; 2016; 48(5):351-354. PubMed ID: 27636207
[TBL] [Abstract][Full Text] [Related]
5. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.
Thomasius R; Zapletalova P; Petersen K; Buchert R; Andresen B; Wartberg L; Nebeling B; Schmoldt A
J Psychopharmacol; 2006 Mar; 20(2):211-25. PubMed ID: 16510479
[TBL] [Abstract][Full Text] [Related]
6. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress.
Parrott AC
J Psychopharmacol; 2006 Mar; 20(2):147-63. PubMed ID: 16510474
[TBL] [Abstract][Full Text] [Related]
7. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a WWW study.
Scholey AB; Parrott AC; Buchanan T; Heffernan TM; Ling J; Rodgers J
Addict Behav; 2004 Jun; 29(4):743-52. PubMed ID: 15135556
[TBL] [Abstract][Full Text] [Related]
8. Key interindividual determinants in MDMA pharmacodynamics.
Papaseit E; Torrens M; Pérez-Mañá C; Muga R; Farré M
Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):183-195. PubMed ID: 29303006
[TBL] [Abstract][Full Text] [Related]
9. Caffeine provokes adverse interactions with 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and related psychostimulants: mechanisms and mediators.
Vanattou-Saïfoudine N; McNamara R; Harkin A
Br J Pharmacol; 2012 Nov; 167(5):946-59. PubMed ID: 22671762
[TBL] [Abstract][Full Text] [Related]
10. MDMA and heightened cortisol: a neurohormonal perspective on the pregnancy outcomes of mothers used 'Ecstasy' during pregnancy.
Parrott AC; Moore DG; Turner JJ; Goodwin J; Min MO; Singer LT
Hum Psychopharmacol; 2014 Jan; 29(1):1-7. PubMed ID: 24424703
[TBL] [Abstract][Full Text] [Related]
11. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA.
Yang J; Jamei M; Heydari A; Yeo KR; de la Torre R; Farré M; Tucker GT; Rostami-Hodjegan A
J Psychopharmacol; 2006 Nov; 20(6):842-9. PubMed ID: 16714321
[TBL] [Abstract][Full Text] [Related]
12. MDMA: interactions with other psychoactive drugs.
Mohamed WM; Ben Hamida S; Cassel JC; de Vasconcelos AP; Jones BC
Pharmacol Biochem Behav; 2011 Oct; 99(4):759-74. PubMed ID: 21756931
[TBL] [Abstract][Full Text] [Related]
13. Sprague-Dawley rats display metabolism-mediated sex differences in the acute toxicity of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy).
Fonsart J; Menet MC; Declèves X; Galons H; Crété D; Debray M; Scherrmann JM; Noble F
Toxicol Appl Pharmacol; 2008 Jul; 230(1):117-25. PubMed ID: 18358511
[TBL] [Abstract][Full Text] [Related]
14. Acute effects of MDMA (3,4-methylenedioxymethamphetamine) on EEG oscillations: alone and in combination with ethanol or THC (delta-9-tetrahydrocannabinol).
Lansbergen MM; Dumont GJ; van Gerven JM; Buitelaar JK; Verkes RJ
Psychopharmacology (Berl); 2011 Feb; 213(4):745-56. PubMed ID: 20924751
[TBL] [Abstract][Full Text] [Related]
15. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview.
Gouzoulis-Mayfrank E; Daumann J
J Psychopharmacol; 2006 Mar; 20(2):188-93. PubMed ID: 16510477
[TBL] [Abstract][Full Text] [Related]
16. MDMA, cortisol, and heightened stress in recreational ecstasy users.
Parrott AC; Montgomery C; Wetherell MA; Downey LA; Stough C; Scholey AB
Behav Pharmacol; 2014 Sep; 25(5-6):458-72. PubMed ID: 25014666
[TBL] [Abstract][Full Text] [Related]
17. Loud noise enhances nigrostriatal dopamine toxicity induced by MDMA in mice.
Gesi M; Ferrucci M; Giusiani M; Lenzi P; Lazzeri G; Alessandrì MG; Salvadorini A; Fulceri F; Pellegrini A; Fornai F; Paparelli A
Microsc Res Tech; 2004 Jul; 64(4):297-303. PubMed ID: 15481049
[TBL] [Abstract][Full Text] [Related]
18. Changes in cardiovascular responsiveness and cardiotoxicity elicited during binge administration of Ecstasy.
Badon LA; Hicks A; Lord K; Ogden BA; Meleg-Smith S; Varner KJ
J Pharmacol Exp Ther; 2002 Sep; 302(3):898-907. PubMed ID: 12183645
[TBL] [Abstract][Full Text] [Related]
19. Deaths involving MDMA and the concomitant use of pharmaceutical drugs.
Pilgrim JL; Gerostamoulos D; Drummer OH
J Anal Toxicol; 2011 May; 35(4):219-26. PubMed ID: 21513615
[TBL] [Abstract][Full Text] [Related]
20. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion.
Farah R; Farah R
Pediatr Emerg Care; 2008 Sep; 24(9):615-7. PubMed ID: 18797371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
